In addition, the combination of BI-D1870 and ipatasertib showed significantly more powerful growth suppression compared to the effect by either ipatasertib or BI-D1870 alone, not only in HMCLs, but also in primary myeloma cells from a patient who acquired resistance to PI, IMiDs, and anti-CD38 MoAb (Figure 2B). Here, CD38 is linked to plasma cell myeloma.